A phase II trial with rosiglitazone in liposarcoma patients.
about
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionChemotherapy and chemoprevention by thiazolidinedionesCommonalities in the Association between PPARG and Vitamin D Related with Obesity and CarcinogenesisCurrent classification, treatment options, and new perspectives in the management of adipocytic sarcomasAdipose-derived stem cells for regenerative medicineNotch activation drives adipocyte dedifferentiation and tumorigenic transformation in miceDifferentiation therapy of leukemia: 3 decades of development.In vivo effects of rosiglitazone in a human neuroblastoma xenograft.PPARgamma Ligand as a Promising Candidate for Colorectal Cancer Chemoprevention: A Pilot Study.Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival.PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcomaAn experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.Advances in the targeted therapy of liposarcoma.Retroperitoneal liposarcoma: current insights in diagnosis and treatmentPleomorphic liposarcoma: clinical observations and molecular variables.Peroxisome proliferator-activated receptors and cancer: challenges and opportunitiesPioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.Emerging treatments for soft tissue sarcoma of adults.Solid tumor differentiation therapy - is it possible?Clinical relevance of peroxisome proliferator-activated receptor-gamma expression in myxoid liposarcoma.Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer.Gene-expression profiling in differentiated thyroid cancer--a viable strategy for the practice of genomic medicine?A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas.The potential of antidiabetic thiazolidinediones for anticancer therapy.Antineoplastic effects of rosiglitazone and PPARgamma transactivation in neuroblastoma cells.Adult human sarcomas. II. Medical oncology.Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trialsPresent concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer.Chondrosarcoma and peroxisome proliferator-activated receptor.PPARgamma: The Portrait of a Target Ally to Cancer Chemopreventive AgentsTo Live or to Die: Prosurvival Activity of PPARgamma in Cancers.Clinical Use of PPARgamma Ligands in Cancer.The prince and the pauper. A tale of anticancer targeted agents.PPAR gamma signaling exacerbates mammary gland tumor development.PPAR Ligands for Cancer Chemoprevention.Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.Integrative Genomic Analyses Yield Cell-Cycle Regulatory Programs with Prognostic ValueThe Role of PPARs in the Endothelium: Implications for Cancer TherapyActivating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis.Testing new regimens in patients with advanced soft tissue sarcoma: analysis of publications from the last 10 years.
P2860
Q24601222-A85D3E14-49FB-44F6-8C9D-82C3C836F512Q27011352-A4635785-F03B-4D61-AAB8-28E1322CA06FQ28070220-49B331EA-E27C-4EBC-99DD-74C0876B6986Q28076210-101AF8AE-3C03-4C36-A16E-455D565AA52CQ28301763-47399B59-0699-42EB-BEE9-4708ABE052FBQ28389770-7A762D54-390E-4014-BED6-A92C51E24549Q33409795-4C25E5F4-E982-4E99-8E0E-474A5C802F38Q33723620-6EA028FF-BAB8-4967-9A06-A58FC5086BC6Q34089258-FAD1B228-202D-4959-80AC-B0609D9BE654Q34633368-E93A513F-4D3A-4E39-9DE7-88F5B297DF95Q34635550-4A8B5774-278A-4F78-AF76-8B8359E4D1B7Q34682291-678E3511-FABA-4739-9F70-52B397760F55Q34952133-CB9A99CD-BEA5-4392-949A-A3F1BDA0368DQ35066363-B15758BB-0A2A-4647-AE35-53B7FBC2610FQ35179511-7FDD9F23-96FB-43F1-840B-9C6B5A04E04CQ35210023-A026F186-E1E9-493C-B58D-365CBB636529Q35417323-06B139AF-6C55-4E87-8AEA-18FB6520A694Q35967402-CC97F8C0-9989-4F1C-A3F6-4867B3252796Q36071880-F70B946A-1DBB-4149-BCF7-3EC823B254D2Q36073121-283CC35F-8267-4A51-B2A4-894508D6161DQ36187022-B5B8968D-EBD5-453D-AD26-0017A727D676Q36429534-C4F7B3E1-9455-4957-8908-EB26196C998EQ36512275-B4653307-195F-4E25-87DD-00F37825E9BCQ36568732-D16DE903-3FBB-472F-A8AE-031B3B816CE4Q36611745-5CCA5B5C-F161-41C2-A24F-E9998AB2447AQ36731430-0C6F7129-B4EC-430D-89FC-FFED273D1B08Q36756632-92DAA618-63DC-4519-B8E7-FD68C855D27BQ36795404-078691F8-7F04-4866-9A09-9DFF3C0F4F2DQ36840323-F4E0C4B5-5A86-4163-AEB4-865269DD9536Q36859555-37E9F149-A98A-423E-BB14-0349800EDA47Q36867693-7A9788C8-462E-4651-86D8-AD2CF6461211Q37021288-DA8B7588-218F-4DDE-A596-7A6F3CB2C5C2Q37042365-6E409216-5A70-4167-ABB7-54DA8F896DA4Q37092279-37B901B7-A6BF-459E-A841-99ED64018F8CQ37165190-DE55BDE8-688A-4421-A892-ABFDB26424FBQ37226800-498C7361-EC6F-4B3D-AA6E-0E91EE00A5A7Q37276814-1B8EDFAB-CEE5-414C-868F-B734F4D164F7Q37337997-F8B83DE1-3EEB-4021-B4F2-903A18A9456CQ37480201-AA194460-D8DF-4D1E-A1D3-A4006BAAF19AQ37823790-80CF9295-FC0E-4335-A298-E50CDC9044D5
P2860
A phase II trial with rosiglitazone in liposarcoma patients.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
A phase II trial with rosiglitazone in liposarcoma patients.
@ast
A phase II trial with rosiglitazone in liposarcoma patients.
@en
type
label
A phase II trial with rosiglitazone in liposarcoma patients.
@ast
A phase II trial with rosiglitazone in liposarcoma patients.
@en
prefLabel
A phase II trial with rosiglitazone in liposarcoma patients.
@ast
A phase II trial with rosiglitazone in liposarcoma patients.
@en
P2093
P2860
P356
P1476
A phase II trial with rosiglitazone in liposarcoma patients.
@en
P2093
A Van Oosterom
V Vanhentenrijk
P2860
P2888
P304
P356
10.1038/SJ.BJC.6601306
P407
P577
2003-10-01T00:00:00Z